TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04936347

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cold knife
Description: Transcervical resection of adhesions is performed with scissors to restore the shape of uterine cavity, promote the regeneration and repair of endometrium, and ultimately improve the reproductive prognosis of patients.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: hot knife
Description: Transcervical resection of adhesions is performed with bipolar electric cutting to restore the shape of uterine cavity, promote the regeneration and repair of endometrium, and ultimately improve the reproductive prognosis of patients.
Study: NCT03821194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gua sha
Description: Scrape the skin around the knee joint

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: hot pack
Description: hot pack
Study: NCT01912534

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valsartan
Description: 40, 80 and 160 mg tablets of Valsartan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: 40, 80 and 160 mg tablets of Valsartan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo
Study: NCT04847180

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biopsy
Description: The biopsy will be performed at the level of the capsular fold located just above the area devoid of cartilage in the postero-superior region of the humeral head, near the area where Hill Sachs notches occur.
Study: NCT01829594

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Case management
Description: Nurses and a physiotherapist (PT) worked as case managers (CM). The intervention lasted 12 months and comprised 4 dimensions. The first was traditional CM tasks: assessment, planning, monitoring, care coordination and evaluation. Home visits were made at least once a month. The second and third was general and specific information related to the participants' situation. The fourth part included aspects of continuity and safety. The PT also paid home visits and made an assessment regarding physical function and balance. The intervention consisted of multidimensional prevention of falls and/or consequences of falls, and supporting and motivating the participant to increased physical activity. When those in the control group had participated for 12 months they were offered the intervention.
Study: NCT03294187

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Wrist-worn wearables
Description: See arm/group description.
Study: NCT01455194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: During the treatment period subjects will inhale two puffs of either 40, 80 or 160 μg ciclesonide in the morning and the evening (corresponding to a total daily dose of 160, 320 or 640 μg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: During the treatment period subjects will inhale two puffs of either 40, 80 or 160 μg ciclesonide in the morning and the evening (corresponding to a total daily dose of 160, 320 or 640 μg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: During the treatment period subjects will inhale two puffs of either 40, 80 or 160 μg ciclesonide in the morning and the evening (corresponding to a total daily dose of 160, 320 or 640 μg)
Study: NCT00699998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Commercially-available Aspirin
Description: Low-dose aspirin, oral, as prescribed by physician through end of study
Study: NCT02459938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon (ZP-Glucagon)
Description: chemically synthesized glucagon as delivered via transdermal microneedle patch system for 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucagon (ZP-Glucagon)
Description: chemically synthesized glucagon as delivered via transdermal microneedle patch system for 30 minutes
Study: NCT01922843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DP001 softgel capsules
Study: NCT02459938

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon (GlucaGen)
Description: recombinant glucagon administered via subcutaneous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon (GlucaGen)
Description: recombinant glucagon administered via subcutaneous injection
Study: NCT01922843

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT05060965

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine lozenge
Description: Nicotine replacement therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine gum
Description: Nicotine replacement therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Nicotine replacement therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maryland Quitline
Description: Telephone-based tobacco cessation service

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: John Hopkins Tobacco Treatment Clinic
Description: Clinic-based tobacco cessation service
Study: NCT02929082

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IRM with a 5-minute- additional sequence to measure FRM
Description: IRM with a 5-minute- additional sequence to measure FRM for patients in group 1,2 and 3

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IRM with a 5-minute- additional sequence to measure FRM
Description: IRM with a 5-minute- additional sequence to measure FRM for patients in group 1,2 and 3

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IRM with a 5-minute- additional sequence to measure FRM
Description: IRM with a 5-minute- additional sequence to measure FRM for patients in group 1,2 and 3
Study: NCT01699074

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 1 gram of White Korean Ginseng
Description: 1 gram of White Korean Ginseng

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 3 grams of White Korean Ginseng
Description: 3 grams of White Korean Ginseng

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 6 grams of White Korean Ginseng
Description: 6 grams of White Korean Ginseng

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 3 grams of Wheat Bran Control
Description: 3 grams of Wheat Bran Control

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 500mg of Korean Red Ginseng
Description: 500mg of Korean Red Ginseng
Study: NCT00772681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel and cisplatin
Description: 3 cycles of docetaxel 75mg/m2 and 100mg/m2 cisplatin combination every 3 weeks
Study: NCT00727558

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nelfilcon A
Description: spherical soft contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: narafilcon A
Description: spherical soft contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: narafilcon A
Description: spherical soft contact lens
Study: NCT02342080

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training sessions
Description: A group with spinal cord injury will be trained in a 30-minute session 5 times weekly for 6 weeks. Each session will be supervised by qualified staff. Patients will undergo training with gradual increase in load and speed, according to the tolerance of each patient. The body weight support progression will start at 50 % of the patient body weight. It will be changed every 2 weeks and the load will decrease 10%. The progression of speed may be accompanied during the training period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lokomat system (Hocoma AG Switzerland)
Description: For the robot locomotion therapy, the Lokomat system (Hocoma AG Switzerland) will be used.
Study: NCT02456857

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV
Study: NCT00076232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir
Description: 400 mg tablet taken orally twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acyclovir placebo
Description: Oral tablet taken twice daily
Study: NCT00658307

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 1 Hz~The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: 20Hz~The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham repetitive transcranial magnetic stimulation (rTMS)
Description: The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)
Study: NCT03337464

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cycling exercise
Description: 5 x 3 minute bouts of cycling exercise separated by 3 minute rest periods

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cycling exercise
Description: 5 x 3 minute bouts of cycling exercise separated by 3 minute rest periods
Study: NCT04455945

Intervention type: PROCEDURE
Intervention: Open Rectal cancer surgery
Description: Open sphincter preserving surgery for rectal cancer

Intervention type: PROCEDURE
Intervention: Laparoscopic Rectal cancer surgery
Description: Laparoscopic sphincter preserving surgery for rectal cancer
Study: NCT02303860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 MR A
Description: Modified release formulation of ORM-12741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 MR A
Description: Modified release formulation of ORM-12741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 MR B
Description: Modified release formulation of ORM-12741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 MR B
Description: Modified release formulation of ORM-12741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 IR
Description: Immediately release formulation of ORM-12741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORM-12741 IR
Description: Immediately release formulation of ORM-12741
Study: NCT04487561

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hemopatch
Description: The patient will be randomized after performing the lymphadenectomy, according to a table of random numbers performed in excel kuytools, then a compression bandage will be performed on all the patients and it will be controlled 24 hours postoperatively, the subsequent control will be weekly until the drain is removed. and / or the disappearance of the seroma

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Aspirative drainage
Description: The patient will be randomized after performing the lymphadenectomy, according to a table of random numbers performed in excel kuytools, then a compression bandage will be performed on all the patients and it will be controlled 24 hours postoperatively, the subsequent control will be weekly until the drain is removed. and / or the disappearance of the seroma
Study: NCT01577342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 0.5%
Description: 1 drop 4 times daily times 3 days post ranibizumab intravitreal injection
Study: NCT02407782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: oral ivermectin, 200μg/kg given at baseline and at day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Permethrin
Description: topical permethrin 5% cream applied at baseline and at day 10.
Study: NCT01461915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab-paclitaxel 125 mg/m2 will be administered IV over 30 minutes. Nab-paclitaxel will be administered weekly for 3 weeks followed by 1 week of rest (28-day cycle).
Study: NCT03855683

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol for The Treatment of Emotional Disorders
Description: Unified Protocol (UP) is is an 8-week intervention designed to specifically benefit individuals who report co-occurring symptoms of anxiety, stress, and mood by providing them with psychoeducation regarding (mal)adaptive emotion regulation, as well as with skills for effectively responding to stress. UP is based on a cognitive-behavioral framework and uses cognitive and behavioral therapy techniques. Each session of UP group therapy is 90 minutes in duration. Sessions themselves generally include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities.
Study: NCT03294187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist-worn wearables
Description: See arm/group description.
Study: NCT03400007

Intervention type: DEVICE
Intervention: Dynamic floor magnetic resonance imaging
Description: Dynamic floor magnetic resonance imaging (MRI)

Intervention type: DEVICE
Intervention: Colpocystodefecography
Description: Colpocystodefecography (CCD)
Study: NCT03841253

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-epithelial PTK
Description: The MEL 90 excimer laser will be used to ablate the corneal epithelium and stroma to a pre-defined depth, using the epithelium as a natural masking agent to smooth the stromal surface.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans-epithelial PTK
Description: The MEL 90 excimer laser will be used to ablate the corneal epithelium and stroma to a pre-defined depth, using the epithelium as a natural masking agent to smooth the stromal surface.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EpiMaster Application Software
Description: The EpiMaster Application Software imports epithelial thickness data and corneal front surface topography data, and uses this to calculate the refractive change that would be induced by a trans-epithelial PTK treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EpiMaster Application Software
Description: The EpiMaster Application Software imports epithelial thickness data and corneal front surface topography data, and uses this to calculate the refractive change that would be induced by a trans-epithelial PTK treatment.
Study: NCT02502136

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: carbon dioxide insufflation during endoscopy
Description: Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: carbon dioxide insufflation during endoscopy
Description: Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: carbon dioxide insufflation during endoscopy
Description: Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: carbon dioxide insufflation during endoscopy
Description: Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Room air insufflation during endoscopy (Placebo)
Description: Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Room air insufflation during endoscopy (Placebo)
Description: Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Room air insufflation during endoscopy (Placebo)
Description: Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Room air insufflation during endoscopy (Placebo)
Description: Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
Study: NCT03406390

Intervention type: PROCEDURE
Intervention: Pterygium surgery
Description: The patients were anesthetized with subconjunctival injection.Symblepharon was released and fibrotic tissue was extensively dissected to expose the sclera and corneal stroma. The subconjunctival fibrovascular tissue, including Tenon's capsule, were thoroughly removed using scissors from the sclera and medial rectus muscle at the area of the superior and inferior fornices and the nasal caruncle. A cryopreserved human amniotic membrane (Zhongshan Ophthalmic Center, China) was then placed on the entire exposed bare sclera with the epithelial side facing upward, and secured with 10-0 nylon sutures.
Study: NCT01180959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10 mg/kg by vein once every 2 weeks on days 1 and 15 of each cycle. The first dose of bevacizumab will be given over about 90 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: 150 mg by mouth once a day.
Study: NCT04078607

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rapid Visual Information Processing task
Description: A series of numbers appeared on a computer screen at a rate of one per minute. Each participant was required to identify any series of three consecutive odd or even numbers by hitting the space bar on the keyboard. The task lasted 15 minutes and included a 1-minute practice session before food being served. Participants were instructed to eat at will while completing the computer task.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: None or Control condition
Description: Participant were instructed to eat at will during a 15-minute duration.
Study: NCT00725972

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Augment O2 Delivery by hemodynamic protocol
Description: Hemodynamic management to a goal of O2 delivery of 600 ml/m2/min utilizing cardiac stroke volume variation with positive pressure ventilation to optimize fluid management.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: High Risk Surgery
Description: Patients with same characteristics as Experimental Group having same types of Surgery but no change to usual anesthetic care
Study: NCT01429285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Attending administers any IV opioid in any dose he chooses
Study: NCT00679406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia
Description: Effective behavioral insomnia treatments are typically delivered over an 8-week period. This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help. The goal here is to test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting \>1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
Study: NCT01549951

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orteronel+Prednisone
Description: Orteronel 400-mg plus prednisone 5-mg will be administered BID orally continuously throughout the treatment cycle of the study.
Study: NCT00561249

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser assisted hatching
Description: Embryos for transfer are subjected to laser assisted hatching(LAH) following the standard procedure.The LAH procedure lasts two minutes per embryo
Study: NCT00624637

Intervention type: OTHER
Group type: OTHER
Intervention: aromatherapy massage
Description: Ten minutes massage of hands, arms or feet with mandarin essential oil 1% (Citrus reticulata) or with carrier oil only

Intervention type: OTHER
Group type: OTHER
Intervention: aromatherapy massage
Description: Ten minutes massage of hands, arms or feet with mandarin essential oil 1% (Citrus reticulata) or with carrier oil only
Study: NCT04020172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: intraoperative fluid administration will be guided by cardiac output monitoring
Study: NCT01342497

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: isoniazide
Description: Tablets, dosing 3 times daily, 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablets, dosing 3 times daily, 12 weeks
Study: NCT01313663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib
Description: oral agent, administered at 800 mg daily (400 mg tablets x 2). Dose can be reduced, interrupted or discontinued due to adverse events or intolerance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed
Description: pemetrexed IV 500 mg/m2 once every 3 weeks
Study: NCT02544191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRHa/ hCG/ hMG
Description: GnRHa was injected subcutaneously at a dose of 3.6mg every 28 days for 5 months. After 2 months from the first GnRHa injection, all subjects were treated with hCG at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG at a dose of 150 IU every 3 days for 2 months.
Study: NCT04907617

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FAW
Description: After the induction of anaesthesia, for patients assigned to groups 1 and 3, the cover of the forced-air warming device (Bair HuggerTM Warming Unit, Model 505, Augustine Medical Inc., Eden Prairie, MN, USA) will be covered over the patient, with the surgical site exposed, and the temperature adjustment of the device will be set to the maximum (43°C). Then, the temperature will be adjusted to maintain a patient temperature of at least 36.5°C. When the patient's body temperature reaches 37°C, the device will be turned off and it will be restarted at a temperature measurement of \<36.5°C.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warmed fluids
Description: In patients assigned to groups 2 and 3, intraoperative IV (Automer blood/fluid warming system, Acemedikal, South Korea) and irrigation fluids (Enthermic Warming Cabinet 1002W, Poland) will be given by heating to 37°C in a thermostatically controlled heating cabinet.